Overview: Herpes Simplex Virus 1 IgM TestIntroduction: The Herpes Simplex Virus 1 IgM Test detects IgM antibodies to HSV-1 to diagnose acute infection, causing sores or fever. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antiviral therapy, and improving outcomes in serology for patients with suspected acute HSV-1 infection, typically presenting as oral herpes or encephalitis.
Other Names: HSV 1 IgM Assay, Acute Herpes Simplex 1 Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: HSV IgM testing began in the 1980s with herpes research. Immunoassays improved in the 1990s, enhancing acute infection detection.
Purpose: Diagnoses acute HSV-1 infection, guides antiviral therapy, and monitors anti-HSV-1 IgM in patients with sores or fever.
Test Parameters: 1. HSV 1 IgM
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like sores, fever, or neurological symptoms, and list medications.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum or CSF within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document sores, fever, neurological symptoms, or history of HSV-1 exposure. Include current medications, especially antivirals, and recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy.
Procedural Considerations: Uses an immunoassay to detect anti-HSV-1 IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for acute herpes diagnosis.
Factors Affecting Result Accuracy: Improper sample handling, early infection, or cross-reactivity with HSV-2 can affect results. False negatives may occur in very early infection.
Clinical Significance: Positive anti-HSV-1 IgM indicates acute HSV-1 infection, prompting antiviral therapy (e.g., acyclovir). Negative results may require repeat testing in early infection.
Specialist Consultation: Consult an infectious disease specialist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: HSV-1 IgG, HSV PCR, or viral culture to confirm acute HSV-1 infection.
Test Limitations: False negatives may occur in early infection. Cross-reactivity with HSV-2 may complicate results. Clinical correlation is needed.
References: IDSA Herpes Guidelines, 2023; Clinical Infectious Diseases, Corey L, 2022.
